Everolimus

Generic Name
Everolimus
Brand Names
Afinitor, Votubia, Zortress
Drug Type
Small Molecule
Chemical Formula
C53H83NO14
CAS Number
159351-69-6
Unique Ingredient Identifier
9HW64Q8G6G
Background

Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication

Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions
Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
Associated Therapies
-
Clinical Trials
Related News

Treg Modulation With CD28 and IL-6 Receptor Antagonists

First Posted Date
2019-08-26
Last Posted Date
2024-10-09
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
24
Registration Number
NCT04066114
Locations
🇺🇸

Cleveland Clinic Foundation: Transplantation, Cleveland, Ohio, United States

🇺🇸

University of California San Francisco School of Medicine: Transplantation, San Francisco, California, United States

🇺🇸

University of Alabama School of Medicine: Transplantation, Birmingham, Alabama, United States

and more 4 locations

Everolimus Monotherapy as Immunosuppression After Liver Transplant

Phase 3
Terminated
Conditions
Kidney Failure
Interventions
Drug: Everolimus
Drug: Tacrolimus
First Posted Date
2019-08-21
Last Posted Date
2023-05-23
Lead Sponsor
Indiana University
Target Recruit Count
14
Registration Number
NCT04063865
Locations
🇺🇸

IU Health University Hospital, Indianapolis, Indiana, United States

Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection

Not Applicable
Recruiting
Conditions
Kidney Transplant Failure and Rejection
Interventions
Drug: Everolimus
First Posted Date
2019-05-20
Last Posted Date
2024-06-06
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
20
Registration Number
NCT03955172
Locations
🇫🇷

Service de transplantation, néphrologie et immunologie clinique, Hôpital Edouard Herriot (HCL), Lyon, France

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

First Posted Date
2019-05-15
Last Posted Date
2024-06-12
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
36
Registration Number
NCT03950609
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

First Posted Date
2019-02-15
Last Posted Date
2024-11-25
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
39
Registration Number
NCT03839940
Locations
🇺🇸

Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States

🇺🇸

Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States

🇺🇸

Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States

and more 316 locations

A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

First Posted Date
2019-02-08
Last Posted Date
2024-08-05
Lead Sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Target Recruit Count
27
Registration Number
NCT03834740
Locations
🇺🇸

HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States

🇺🇸

St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States

🇺🇸

Chandler Regional Medical Center, Chandler, Arizona, United States

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

First Posted Date
2018-11-14
Last Posted Date
2024-10-24
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
45
Registration Number
NCT03740334
Locations
🇺🇸

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

🇺🇸

Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States

and more 9 locations

Itacitinib + Everolimus in Hodgkin Lymphoma

Phase 1
Active, not recruiting
Conditions
Classical Hodgkin Lymphoma
Interventions
Drug: Itacitinib
Drug: Everolimus
First Posted Date
2018-10-05
Last Posted Date
2024-11-14
Lead Sponsor
University of Pennsylvania
Target Recruit Count
23
Registration Number
NCT03697408
Locations
🇺🇸

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

First Posted Date
2018-09-06
Last Posted Date
2024-07-10
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
103
Registration Number
NCT03659136
Locations
🇧🇪

Brussels - UNIV Saint-Luc, Bruxelles, Belgium

🇧🇪

UZ Leuven, Leuven, Belgium

🇺🇸

Cancer Treatment Centers of America at Western Regional Medical Center, Goodyear, Arizona, United States

and more 51 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy